Prevalence of Wildtype Amyloid After TAVR

North Florida Foundation for Research and Education

Status: Withdrawn

Conditions: Amyloidosis

Study type: Observational

Funder types: Other

Identifiers

NCT03825406

#: 201802928

Details and patient eligibility

About

Those with abnormal vital signs after TAVR need to be willing to obtain a bone scan to evaluate for wildtype amyloidosis. Positive bone scan findings will require evaluation for primary amyloidosis with blood and urine monoclonal immunoglobulin testing. Primary amyloidosis is a different type of disease which requires different treatment.

Full description

This research is interested in determining how common wildtype amyloidosis is after transcatheter aortic valve replacement (TAVR). Amyloidosis is a condition characterized by abnormal protein which can accumulate and impair various organs, including the heart. Research suggests that amyloidosis might be common among TAVR patients, but it is a condition that is not routinely evaluated for. We suspect that wildtype amyloidosis may be especially common among patients with abnormal vital signs after their TAVR procedure.

Sex: All

Ages: 50 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Patients that underwent a TAVR procedure at the Malcolm Randall VA Medical Center.
• Implant of current generation TAVR (i.e. Sapien S3, Evolut R, or Evolut Pro).
• Willingness to obtain bone scintigraphy if evidence of impaired hemodynamics after valve deployment.
• Willingness to have blood drawn
• Willingness to complete SF12 quality of life KCCQ

Exclusion Criteria:

--Patient that do not qualify for a TAVR procedure as normal clinical care